Management’s plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.
If you own Johnson & Johnson (JNJ) for its breadth, the past year has been kind
The stock is up close to 60% against about 20% for the S&P 500, and it sits near its 52-week high. What has quietly changed is not the performance. It is what the company calls itself.
The Health Care Company That Now Calls Itself An Innovation Powerhouse A year and a half ago the label management led with was deliberately plain: this was a health care company. Orthopedics sat inside that story as an ordinary reporting line, with growth of 1.3% credited, a little earlier still, to recent product launches. The self-description has since narrowed.